iSpecimen operates an online marketplace platform that facilitates transactions between life science researchers and biospecimen providers. The company's proprietary iSpecimen Marketplace connects biopharmaceutical companies, in vitro diagnostic companies, and academic/government institutions with hospitals, laboratories, and other organizations that supply human biospecimens. The platform enables researchers to source biospecimens needed for drug development, diagnostic testing, and research applications.
The marketplace catalog includes multiple biospecimen categories. Biofluids offerings encompass whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebrospinal fluid. Solid tissue products include fresh, fixed, and cryopreserved tissue samples, as well as formalin-fixed paraffin embedded blocks, slides, and curls. The company also provides hematopoietic stem and immune cells derived from bone marrow, cord blood, and whole blood, including isolated cell types such as peripheral blood mononuclear cells.
The company operates with 24 full-time employees and is headquartered in Woburn, Massachusetts. iSpecimen was incorporated in Delaware in 2009 and trades on the Nasdaq exchange. The company serves a global client base of pharmaceutical, diagnostic, and research organizations that require access to human biospecimens for preclinical and clinical research purposes.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-17.58 | $-17.58 | -1329.3% | |
| 2023 | $-1.23 | $-1.23 | -6.0% | |
| 2022 | $-1.16 | $-1.16 | +44.5% | |
| 2021 | $-2.09 | $-2.09 | — |